Your questions about Teva’s environmental goals answered

Teva Pharmaceutical Industries has announced long-term environmental sustainability commitments and targets to provide direction and drive action in this area. You can explore these targets here.

What were Teva’s previous environmental goals?

Toggle

We set 2020 goals in 2014, which we retired in 2019, as we either achieved them or they were no longer applicable.

To ensure we didn’t lose momentum, we established a new interim greenhouse gas (GHG) goal, while we developed next generation, long-term environmental sustainability targets.

The interim GHG goal was to achieve a 10% absolute reduction in Scope 1 and 2 emissions from our 2017 baseline (adjusted for business divestitures and plant closures) by the end of 2020, and we already significantly exceeded this, one year ahead of schedule.

What is the difference between Scope 1, 2 and 3 greenhouse gas emissions?

Toggle

Scope 1 describes all direct emissions from our activities or under our control. This may include fuel combustion from gas boilers, fleet vehicles or air-conditioning leaks.

Scope 2 describes indirect emissions from the creation of electricity that we purchase and use.

Scope 3 describes all other indirect emissions resulting from sources we do not own or control in our value chain. These include emissions associated with purchased materials and services, shipping and logistics, business travel, waste and water.

What is the Paris Climate Agreement?

Toggle

The Paris Climate Agreement is an agreement with the United Nations Framework Convention on Climate Change (UNFCCC), adopted by 197 countries in December 2015.

The central aim is to strengthen the global response to the threat of climate change by keeping a global temperature rise this century well below 2° Celsius compared to pre-industrial levels, and to pursue efforts to limit the temperature increase even further to 1.5° Celsius.

How does Teva align with the United Nations Sustainable Development Goals (SDGs)?

Toggle

The SDGs are 17 goals set by the UN in 2015 to end poverty, protect the planet and ensure all people enjoy peace, prosperity and health, as part of the 2030 Agenda for Sustainable Development.

With a mission focused on improving health, Teva inherently supports the SDGs, particularly Goal 3: Good Health and Well-Being.

We also support several other SDGs, including Goal 7: Affordable and Clean Energy, Goal 8: Decent Work and Economic Growth, Goal 10: Reduced Inequalities, Goal 13: Climate Action and Goal 17: Partnerships for the Goals.

What is anti-microbial resistance?

Toggle

Read ‘Rise of the Superbugs: 5 Key Questions Answered’ to discover more about AMR.

What is Teva doing to address antimicrobial resistance (AMR)?

Toggle

As the manufacturer of 70% of the listed antibiotics/anti-infectives that appear on the World Health Organization’s Essential Medicines List (21st List, 2019), we are dedicated to addressing the threat of AMR.

We are minimizing antimicrobial discharges across 100% of Teva production (100% assessed by 2021; 95% volume and sites assessed to date) and 50% of our antimicrobial supply chain, in line with the AMR Industry Alliance commitments.

Where can I find more information about Teva’s environmental sustainability record?

Toggle

Click here to access our latest Environment, Social and Governance Report, which contains more information about Teva’s record


Find out more

    Cautionary Note Regarding Forward-Looking Statements

    Toggle

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Teva’s environmental goals, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.

    Important factors that could cause or contribute to such differences include risks relating to:

    • our ability to impact and effectively execute on our social, economic, environment and governance related strategy and goals;
    • our ability to successfully compete in the marketplace; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general, including: uncertainty regarding the magnitude, duration, and geographic reach of the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; effectiveness of our restructuring plan announced in December 2017; our ability to attract, hire and retain highly skilled personnel; our ability to develop and commercialize additional pharmaceutical products; compliance with anti-corruption sanctions and trade control laws; manufacturing or quality control problems; interruptions in our supply chain, including due to potential effects of the COVID-19 pandemic on our operations and business in geographic locations impacted by the pandemic and on the business operations of our suppliers; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including adverse effects of the COVID-19 pandemic, political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers; compliance, regulatory and litigation matters, including: our ability to successfully defend against the U.S. Department of Justice criminal charges of Sherman Act violations; increased legal and regulatory action in connection with public concern over the abuse of opioid medications in the U.S. and our ability to reach a final resolution of the remaining opioid-related litigation; costs and delays resulting from the extensive governmental regulation to which we are subject or delays in governmental processing time due to modified government operations due to the COVID-19 pandemic, including effects on product and patent approvals due to the COVID-19 pandemic; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into S&M practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; environmental risks and other financial and economic risks;

    and other factors discussed in this press release, in our Quarterly Reports on Form 10-Q for the first, second and third quarters of 2020 and in our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned "Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-loo

    Share this article: